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DOI 10.1186/s13195-015-0141-2RESEARCH Open AccessRe-examining tau-immunoreactive pathology
in the population: granulovacuolar
degeneration and neurofibrillary tangles
Sally Hunter1*, Thais Minett1,2, Tuomo Polvikoski3, Elizabeta Mukaetova-Ladinska3, Carol Brayne1
and the Cambridge City over-75s Cohort CollaborationAbstract
Introduction: Alzheimer’s disease (AD) is associated with neurofibrillary pathology, including neurofibrillary tangles
(NFT), neuritic plaques (NP) and neuropil threads containing aggregated microtubule associated protein tau.
Aggregated tau is also associated with granulovacuolar degeneration (GVD). The relationships between tau, GVD,
NFT and dementia are unclear.
Methods: We assessed hippocampal (CA1) tau-immunoreactive GVD and NFT pathology in brain donations from
the population-representative Cambridge City over 75s Cohort (CC75C) using the CERAD protocol and a modified
protocol that included a morphological characterisation of tau-immunoreactive deposits within neurons as NFTs or
as GVD. Associations between GVD, NFT and dementia were investigated.
Results: Hippocampal pyramidal neurons affected with either NFT or GVD are common in the older population.
Some tau-immunoreactive deposits resemble ghost GVD neurons. Tau immunoreactivity identified GVD in 95 %
cases rated as none with haematoxylin and eosin staining. Both severe NFT (odds ratio (OR) 7.33, 95 % confidence
interval (CI) 2.01; 26.80, p = 0.003) and severe GVD (OR 7.48, 95 %(CI) 1.54; 36.24, p = 0.012) were associated with
dementia status. Increasing NFT (OR 2.47 95 %(CI) 1.45; 4.22, p = 0.001) and GVD (OR 2.12 95 %(CI) 1.23; 3.64, p = 0.007)
severities are associated with increasing dementia severity. However, when the analyses were controlled for other
neuropathologies (NFT, NP, Tar-DNA binding Protein-43 and amyloid deposits), the associations between GVD and
dementia lost significance.
Conclusions: Current neuropathological assessments do not adequately evaluate the presence and severity of the
GVD pathology and its contribution to dementia remains unclear. We recommend that protocols to assess GVD should
be developed for routine use and that tau, in a non-PHF associated conformation, is reliably associated with GVD.Introduction
Alzheimer’s disease (AD) is characterised clinically by
memory loss, cognitive impairment and behavioural
problems [1], and neuropathologically by neuronal and
synaptic loss and by various deposits containing the
amyloid-beta protein (Aβ) and aggregated microtubule-
associated protein tau in the form of neurofibrillary
pathologies including neurofibrillary tangles (NFT),* Correspondence: seh66@medschl.cam.ac.uk
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pil threads (NT) [2]. Assessments of these lesions form
the basis for the neuropathological confirmation of a
clinical diagnosis of probable AD according to the Con-
sortium to Establish a Registry for Alzheimer’s Disease
(CERAD) protocol [2, 3] and the assessment of tau-
immunoreactive (IR) changes according to Braak stage
[4, 5]. The assessments for neuropathologically diagnos-
ing AD have been updated recently to include assess-
ments of Aβ deposits [6, 7].
The tau-associated pathologies, visualised by various
methods and assessed using both the CERAD protocol
[2, 3] and Braak staging [5, 8], include NFT, NP and NT.
NFT are intracellular fibrous inclusions composed ofe is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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hyperphosphorylated tau [9]. The CERAD protocol [2, 3]
counts only those neurons with mature, robustly staining
NFT; those neurons with diffuse or granular staining
are classified as pre-tangles and are not counted. The
morphology of tau-IR cytoplasmic inclusions is not
considered. The presence of extracellular ghost NFT,
the remains of NFT after the neuron has died, are
noted in both CERAD and Braak staging. These are
assessed on haematoxylin and eosin (H & E) or silver
stained slides because many tau-IR epitopes associated
with NFT are lost [10].
In addition to the well-recognised AD-associated path-
ologies and argyrophilic grains in argyrophilic grain dis-
ease (AGD) [11], various studies have demonstrated that
the dense granules of granulovacuolar degeneration
(GVD) also react with tau antibodies directed against
various epitopes [10, 12–15] but not those directed
against some conformational epitopes specific for PHFs
[16, 17]. The possibility of potential confusion relating to
the interpretation of tau-IR pathology has been noted pre-
viously [15]. GVD, first described by Teofil Simchowicz
[18], is characterised by neurons with two or more double
membrane-bound cytoplasmic vacuoles containing an
electron-dense granule [19] and are usually assessed on
H & E slides. GVD is noted in the CERAD protocol as
present or absent in the hippocampus [2, 3]. GVD is
distinct from other tau-IR granules described previously
that lack membrane enclosed vacuoles and have been
interpreted as PHF core bodies [20].
GVD within hippocampal pyramidal cells has previously
been associated with increasing age and AD [21–23]
and is associated with intraneuronal accumulation of
tau protein [21]. GVD is also found in other neurode-
generative disorders, including Pick’s disease, multiple
system atrophy with Parkinsonism, amyotrophic lateral
sclerosis with dementia, Down syndrome and progres-
sive supranuclear palsy [15, 24, 25]. Previous work has
suggested a possible progression of development for
GVD [23, 26], ranging from a few cytoplasmic granulo-
vacuolar inclusions to neurons completely filled with
granulovacuolar inclusions, which may follow topo-
graphical stages [15, 27]. While the association of GVD
with AD has long been noted [12, 21], a recent study
estimating the contributions of rare or disregarded
pathologies [28] found no significant association be-
tween GVD and dementia when plaques and tangles
were controlled for—raising questions relating to the
significance of GVD to dementia.
The literature reviewed suggests that the relationship
between GVD and dementia is unclear and that there is
potential for confusion in interpretations of tau-IR path-
ologies. We examined the pathology of tau-IR GVD and
NFT in detail in the cornus ammonis (CA) fields of thehippocampus in the population-based Cambridge City
over-75s Cohort (CC75C) with an antibody against the
C-terminal portion of tau that is not dependent on phos-
phorylation or PHF-specific epitopes. We categorised
neuronal tau pathology as NFT, GVD or mixed (NFT
+GVD), and investigated how this detailed morphology
relates to current assessments of GVD and tau pathology
according to well-accepted protocols and relates to the
associations between NFT, GVD and dementia.
Materials and methods
The study sample
CC75C is a population-based, longitudinal study of aging
and dementia with a brain donation programme [29].
Each study participant gave consent to participate and for
brain donation. Consent for brain donation was also given
by next of kin. Each phase of the CC75C study has been
approved by the Cambridge Research Ethics Committee.
At the time of this study a total of 237 brain donations
had CERAD measures, of which 211 cases were included
for all analyses. Twenty five slides were not available or
the area of interest was not present on the slide to score
tau-IR GVD, NFT and GVD+NFT. For one slide, CA1
was not evaluable owing to complete neuronal loss.
A consensus diagnosis for dementia status at death
consistent with Diagnostic and Statistical Manual of
Mental Disorders 4th edition (DSM-IV) criteria [30] was
agreed by clinicians, blinded to neuropathology reports,
using post-mortem review of all clinical information in-
cluding proxy informant data, death certificates and retro-
spective informant data after death. Dementia severity was
rated as none, minimal, mild, moderate and severe [31].
Where dementia severity could not be rated it was scored
as unknown.
Neuropathological protocols
Brain collection for this study occurred between 1989
and 2009. After death, the brains were removed as soon
as possible in the local mortuary. The brains were
bisected in the sagittal plane. One cerebral hemisphere
was dissected coronally into approximately 1 cm slices,
macroscopically examined and then snap-frozen to –80 °C.
The other half of the brain was fixed in formalin for at
least 6 weeks and dissected coronally into approximately
1 cm slices. For diagnostic purposes, tissue blocks for par-
affin embedding were taken from the hippocampus (at the
level of the lateral geniculate body), entorhinal cortex (at
the level of the mammillary body), frontal, temporal, par-
ietal and occipital lobes, basal ganglia, thalamus, pons,
medulla, cerebellum and two levels of the midbrain. Serial
sections from the paraffin-embedded brain tissue samples
were assessed for neuropathology blind to clinical status
according to the CERAD protocol [2, 3] and Braak stage
[4, 5]. All slides were produced by the Cambridge Brain
Table 1 Inter-rater reliability on tau-IR GVD, NFT and GVD+NFT
by hippocampal area
AC2 SE 95 % CI (AC2) p value
CA2–3
NFT 0.73 0.11 0.51–0.95 <0.001
NFT+GVD 0.13 0.22 −0.33 to 0.58 0.568
GVD 0.67 0.09 0.49–0.85 <0.001
CA1
NFT 0.89 0.06 0.77–1.00 <0.001
NFT+GVD 0.76 0.09 0.57–0.96 <0.001
GVD 0.76 0.08 0.60–0.92 <0.001
AC2 Gwet’s coefficient, CA cornus ammonis, CI confidence interval, GVD
granulovacuolar degeneration, NFT neurofibrillary tangles, SE standard error
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blind to clinical status by neuropathologists at Adden-
brooke’s Hospital, Cambridge, UK. All immunostained
sections for diagnosis were counterstained with Ehrlich’s
haematoxylin with diaminobenzidine as the chromagen.
Lewy bodies were assessed as present or absent using
10 μm sections stained with H & E in combination with
slides stained with anti-ubiquitin antibody (pAb BR 251,
Z0458; DAKO, Glostrup, Denmark) (first 174 donations)
or with anti-α-synuclein (SA3400; Biomol International,
Enzo Life Sciences, Farmingdale, New York, USA) (last
63 cases). Aβ deposits as senile plaques and cerebral
amyloid angiopathy (CAA) were visualised with Congo
red and/or anti-Aβ antibody (M872, Clone 6 F/3D;
DAKO) on 10 μm sections and assessed as none, mild,
moderate or severe according to the CERAD protocol [2].
Inclusions reactive with tar-DNA binding protein 43
(TDP-43) were assessed using 9 μm sections from the
hippocampus and entorhinal cortex stained with anti-
TDP-43 antibody (pS409/410-2; Cosmo Bio Co. Ltd,
Tokyo, Japan). Slides were counterstained with Harris’
haematoxylin with diaminobenzidine as the chromagen.
Solid neuronal inclusions were assessed, based on the
protocol in Neumann et al. [32], as none (no inclusions),
minimal (one inclusion per slide), mild (one or more inclu-
sions in up to half the fields of view per slide), moderate (a
few inclusions in over half the fields of view per slide) or
severe (a few inclusions in most fields of view per slide).
Sections 10 μm thick from the hippocampus and ento-
rhinal cortex were immunostained with anti-tau monoclo-
nal antibody (mAb) 11.57 (supplied by The Cambridge
Brain Bank, dilution 1:5; gift donated by Professor Claude
Wischik, University of Aberdeen, UK) to visualise NFT,
NP and dystrophic neurites. mAb 11.57 was raised against
a pronase-treated PHF core sub-fraction and recognises a
phosphorylation and conformation-independent epitope
in the C-terminal region of tau [12]. mAb 11.57 recognises
NFT, NP, NT and GVD bodies and the grains of AGD but
not ghost NFT [12, 33]. During the diagnostic process, an
experienced neuropathologist scored the severity of NFT
according to the CERAD protocol [2, 3] as either none,
mild, moderate or severe. GVD, defined as neurons with
two or more membrane-bound cytoplasmic vacuoles con-
taining a basophilic granule, was rated according to the
CERAD protocol [2, 3] as present or absent on hippocam-
pal sections 10 μm thick stained with H & E.
A second protocol was designed to assess the separate
tau-IR pathologies based on morphology. Tau-IR NFT
(defined as neurons with fibrous deposits of tau and no
vacuoles containing an electron dense granule), tau-IR
GVD (defined as neurons with two or more membrane-
bound cytoplasmic vacuoles containing a tau-IR dense
granule and no fibres) and neurons containing mixed path-
ology with both fibrous and granulovacuolar pathology(NFT+GVD) were scored at 100× magnification as
none, an isolated example per area, and as mild, moder-
ate or severe by comparison with the references images
for NFT from the CERAD protocol [3]. The same slides
were assessed with both protocols. Higher magnifica-
tions (200× and 400×) were used to assess the detailed
morphology of any tau-IR structures that could not be
classified at lower magnification (100×). Separate scores
for the hippocampal regions CA1 and CA2–3, the re-
gions most associated with tau immunoreactivity, were
generated by SH and inter-rated by TP. Regions CA2
and CA3 were combined for scoring owing to difficul-
ties in reliably defining the CA2–CA3 boundary. Photo-
micrographs were taken with a Leica DM LB microscope
with a DC500 digital camera Wetzlar, Germany.Inter-rater analysis
The extent of agreement between two raters (SH and
TP) in relation to severity of NFT, GVD and NFT+GVD
in CA1 and CA2–3 was assessed by calculating Gwet’s
AC2 coefficients (Table 1). This is a paradox-resistant al-
ternative to Kappa’s coefficient when the overall percent-
age agreement is high [34]. The coefficient calculations
were performed using Agreestat 2011.2 (Advanced
Analytics, Gaithersburg, MD, USA). The extent of
agreement was assessed using the benchmark proposed
by Landis and Koch [35]; a coefficient >0.6 indicates
substantial agreement and a value >0.8 near-perfect
agreement. In general, NFT and GVD were seen to have
AC2 coefficients >0.6, implying substantial agreement,
which was more marked in CA1 (Table 1). The only
exception was for NFT+GVD in CA2–3 (AC2 = 0.13),
where agreement was poor. This was most probably due
to a combination of differences in assigning the CA1/
CA2 boundary and the rarity of neurons with both tau-
IR NFT and GVD pathologies. Data for NFT+GVD were
not included in further analyses.
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Inter-rater reliability was not substantial for NFT+GVD
in CA2–3, so further analyses were restricted to NFT
and GVD in the CA1 area only. The mean (standard de-
viation) is presented when applicable.
The relationships between tau-IR GVD and NFT with
dementia status were verified using logistic regression.
Dementia status was defined as the dependent variable
and tau-IR scores in CA1 as independent variables.
Three hierarchical models were created: model 1 con-
trolled for sex and age at death; model 2 was additionally
controlled for NFT and NP; and model 3 additionally
controlled for TDP-43 and amyloid deposits. The same
approach was used to verify the relationships between
tau-IR GVD and NFT with dementia severity, using or-
dinal logistic regression.
The Spearman coefficient (r) was calculated to verify
the relationships between different pathologies and dif-
ferent protocols. All tests were two-tailed. Statistical ana-
lyses were performed using statistical package STATA,
version 12 College Station, Texas, USA.
Results
In total, 211 brains were included in the sample. Among
them, 147 (70 %) were women. Mean age of death was
90.97 (4.51) years. Dementia status at death could not be
determined in eight (4 %) participants, 71 (34 %) did not
have dementia and 132 (63 %) had dementia at death.
Both NFT and GVD were common; using the new
protocol, 91 % of the cases surveyed showed both GVD
and NFT in the hippocampal CA1 fields, 1 % had NFT
with no GVD, 4 % had GVD with no NFT and 4 % had
neither NFT nor GVD pathology.
Relationship between CERAD assessments and the new
protocol
Table 2 presents a comparison between CERAD protocol
GVD scores (columns) and the morphologically sepa-
rated tau-IR GVD scores from the modified protocol
(rows). Assessments using H & E slides underestimated
GVD pathology: 95 % (54/57) of cases scored as havingTable 2 Comparison of GVD scores from the two protocols
CERAD protocol GVD score
Tau-IR GVD scorea No Yes
No 3 (5) 1 (1)
Mild 21 (37) 18 (26)
Moderate 21 (37) 31 (45)
Severe 12 (21) 19 (28)
Data presented as n (%). Some GVD scores were marked as missing from the
CERAD assessment, and therefore data are for cases which did have CERAD
GVD scores (n = 126)
aFrom the modified protocol
CERAD Consortium to Establish a Registry for Alzheimer disease, GVD
granulovacuolar degeneration, IR immunoreactiveno GVD according to the CERAD protocol were scored
as having at least mild GVD in CA1 according to the
tau-IR stain.
Table 3 compares CERAD scores for NFT with those
from the new protocol. Even though both the CERAD
protocol and our modified tau-IR protocol scores repre-
sent the CA1 area, the correlation between those NFT
scores was moderate (n = 126, r = 0.67, p <0.001).
Relationship between NFT and GVD
Table 4 compares the scores for NFT and GVD accord-
ing to the CERAD protocol assessments.
There was no significant correlation between NFT and
GVD assessed with the CERAD protocol (n = 126, r=−0.03,
p= 0.760).
Table 5 compares the scores for NFT and GVD ac-
cording to the new tau-IR protocol.
There was moderate correlation between NFT and
GVD using the new tau-IR protocol (n = 211, r = 0.65,
p <0.001).
Relationships between dementia and tau-IR pathologies
Analyses for tau-IR were conducted on 211 brain dona-
tions. Only two cases with hippocampal Lewy body
pathology and only a few cases with moderate/severe
CAA were identified; these neuropathologies were there-
fore not included in further analyses. The distributions
between dementia severity and various hippocampal
neuropathologies are shown in Additional file 1.
The relationship between dementia and tau-IR GVD
was verified by logistic regression with dementia status
as the dependent variable and tau-IR GVD in CA1 status
as the independent variable. The analysis was controlled
by sex and age at death in model 1 (Table 6). Severe tau-
IR GVD was significantly related to dementia regardless
of sex and age of death; however, when the analyses were
also controlled by NFT and NP (Table 6, model 2), the
relationship between dementia and severe tau-IR GVD
lost significance. The loss of significance remained
when hippocampal TDP-43 and amyloid deposits (see
Additional file 1) were controlled for (Table 6, model 3).Table 3 Comparison of NFT scores from the two protocols
CERAD protocol NFT score
Tau-IR NFT scorea No Mild Moderate Severe
No 2 (67) 8 (17) 4 (5) 2 (3)
Mild 1 (33) 31 (67) 26 (32) 3 (4)
Moderate 0 (0) 7 (15) 40 (49) 27 (34)
Severe 0 (0) 0 (0) 11 (14) 48 (60)
Data presented as n (%). One score for NFT was marked as missing, and
therefore data are for cases which did have CERAD NFT scores (n = 210)
aFrom the modified protocol
CERAD Consortium to Establish a Registry for Alzheimer disease, IR
immunoreactive, NFT neurofibrillary tangles
Table 4 Relationship between CERAD scores for NFT and GVD
CERAD protocol NFT score
CERAD protocol GVD score No Mild Moderate Severe
No 1 (100) 15 (43) 18 (43) 23 (48)
Yes 0 (0) 20 (57) 24 (57) 25 (52)
Data presented as n (%)
CERAD Consortium to Establish a Registry for Alzheimer disease, GVD
granulovacuolar degeneration, NFT neurofibrillary tangles
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verity of tau-IR GVD and NFT were tested using ordinal
logistic regressions controlling for sex and age at death
in model 1 (Table 7). For these analyses, tau-IR scores
were dichotomised into none/isolated/mild vs. moderate/
severe. Increasing tau-IR GVD and tau-IR NFT severities
were significantly associated with increasing dementia se-
verity (Table 7, model 1). However, when the analysis was
also controlled by NFT and NP (see Additional file 1), the
relationship between dementia severity and tau-IR GVD
was weaker and lost significance (Table 6, model 2). The
loss of significance remained when hippocampal TDP-43
and amyloid deposits (see Additional file 1) were con-
trolled for (Table 6, model 3).
Descriptions of tau-IR pathology
Hippocampal pyramidal neurons can develop NFT, GVD
or, less commonly, co-existing GVD and NFT as illus-
trated in Fig. 1.
In Fig. 2a, GVD granules in neurons can be seen to
range from a few weakly staining, and very rarely, non-
staining granules within a neuron to an increasing num-
ber of membrane-enclosed granules until the whole cell
body is filled with intensely staining GVD. Distended
neuronal bodies with large swollen GVD bodies can also
be seen (Fig. 2a, neuron 5). This can be compared with
the well-accepted progression in NFT ranging from a
few lightly stained cytoplasmic filaments (Fig. 2b, c, neu-
rons i) to robustly staining mature fibrous NFT (Fig. 2b,
c, neurons ii), with ghost NFT as an end stage (Fig. 2d,
area iii). There is a possibility that advanced stages of
GVD could be mistaken for NFT, as seen in Figs. 1 and
2. The CA2 area at low power in Fig. 1 appears toTable 5 Relationship between new protocol scores for NFT and
GVD
NFT score from tau-IR protocol
GVD score from tau-IR protocol No Mild Moderate Severe
No 8 (50) 1 (2) 0 (0) 2 (3)
Mild 7 (44) 38 (62) 9 (12) 3 (5)
Moderate 1 (6) 22 (36) 45 (60) 21 (36)
Severe 0 (0) 0 (0) 21 (28) 33 (56)
Data presented as n (%)
GVD granulovacuolar degeneration, IR immunoreactive, NFT
neurofibrillary tanglescontain at least three neurons with robustly staining
cytoplasmic inclusions, but at higher magnifications only
one neuron from the marked area contains NFT, with
others showing advanced GVD or a combination of
GVD-like and fibrous inclusions.
Very rarely, neurons with GVD also contained one or
more discrete fibrous bundles (Fig. 1b, neuron 5) that
could not be classified as NFT or GVD/NFT mixed and
so were not included in the assessments. Pyramidal neu-
rons with diffuse cytoplasmic tau reactivity, often with a
defined line around the nucleus (Fig. 1b, neurons 4) and
previously described in association with AGD [36], seen
in the hippocampal areas CA1, CA2 and CA3 were also
not included in assessments for this study.
In addition to the well-recognised ghost tangles as-
sociated with NFT, we also found what appeared to
be extracellular ghost GVD, showing clear granulova-
cuolar inclusions but no evidence of a living neuron,
examples of which are shown in Fig. 3. Unlike ghost
NFT, these retained reactivity with mAb 11.57.
Discussion
We found more GVD pathology using tau-IR than was
detected by H & E, suggesting that GVD is missed with
current protocols. The associations between dementia
and both hippocampal (CA1) NFT and GVD are signifi-
cant. Additionally, the severity of both NFT and GVD
were significantly associated with dementia severity.
However, the association between GVD and dementia
lost significance when NFT, NP and other pathologies
were controlled for.
We find that there is a potential for misinterpretation
of tau pathology. Since many anti-tau antibodies react
with both NFT and GVD, there is potential for neurons
with GVD to be mistaken for pre-tangles and neurons
with severe GVD to be mistaken for NFT at low magnifi-
cations. We also found tau-IR deposits resembling ghost
GVD neurons that appeared morphologically different
from ghost NFT.
This study has limitations. The selection of anti-tau
immunostained slides used in this study was from the
historical diagnostic collection and assessments were
semi-quantitative and not stereological [37]; this may
introduce bias because we assume a single slide will rep-
resent a specific case adequately. Since comparison of
the scoring protocols required that we use the same
diagnostic slides, missing slides—perhaps due to break-
age over the ~25 years of the study to date—may intro-
duce bias.
Our assessments of Lewy bodies are based on older
protocols for 174/241 cases and therefore scores for
Lewy bodies might be underestimates. Both hippocampal
Lewy bodies and CAA were rare and not included in
analyses.
Table 6 Logistic regression models showing the relationships between hippocampal pathologies and presence of clinical dementia
Model 1 Model 2 Model 3
OR CI p value OR CI p value OR CI p value
GVD-IR
Mild 1.04 (0.25–4.38) 0.956 1.00 (0.23–4.35) 1.000 1.00 (0.22–4.52) 0.998
Moderate 1.55 (0.38–6.31) 0.542 1.07 (0.24–4.76) 0.931 1.03 (0.22–4.80) 0.972
Severe 7.48 (1.54–36.24) 0.012 3.90 (0.71–21.45) 0.118 3.81 (0.65–22.41) 0.139
NFT-IR
Mild 1.21 (0.37–3.93) 0.753 1.26 (0.38–4.25) 0.705 1.39 (0.36–5.45) 0.635
Moderate 2.27 (0.70–7.31) 0.170 1.66 (0.46–5.98) 0.435 2.61 (0.61–11.19) 0.198
Severe 7.33 (2.01–26.80) 0.003 4.86 (1.17–20.28) 0.030 9.99 (1.97–50.54) 0.005
Model 1 controlling for age and sex; model 2 additionally controlling for NFT and NP; model 3 additionally controlling for TDP-43 and amyloid deposits
CI confidence interval, GVD granulovacuolar degeneration, IR immunoreactive, NFT neurofibrillary tangles, NP neuritic plaques, OR odds ratio, TDP-43 Tar-DNA binding
protein 43
Hunter et al. Alzheimer's Research & Therapy  (2015) 7:57 Page 6 of 10In any study of this type, brains donated at death rep-
resent a cross-section of the cohort at a specific terminal
point. While the presentation of GVD morphology in
Fig. 2 appears to represent a progression of increasing
severity, this is not certain. Additionally, the morpho-
logical similarity of structures in Fig. 3 to ghost GVD
neurons is circumstantial. These interpretations would
need to be confirmed by longitudinal studies.
Of the 211 cases included in our study, only 126 had
measures for GVD from the CERAD protocol. It is pos-
sible that GVD was not seen on H & E staining and
therefore no measure was recorded. Alternatively, histor-
ically GVD has not been prioritised as a dementia-
related pathology and therefore GVD assessments may
have been neglected. We did not use a second marker
for GVD; however, we were very careful to count only
neurons containing two or more structures with a dense
granule surrounded by the halo of a vacuole and it is un-
likely that we have overestimated GVD. A marker for
GVD has yet to be validated and, given our poor correla-
tions between GVD and NFT as assessed using the
CERAD protocol, a consensus regarding the reliability of
GVD markers is required.
Tau-IR reliably marks nearly all dense granules associ-
ated with GVD and we identified more cases with tau-IR
GVD than with the standard assessment protocol using
H & E staining. Similarly, a study using antibodies to
tubulin found four times more GVD than H & E aloneTable 7 Ordinal logistic regression models showing the relations
clinical dementia
Model 1 Model 2
OR CI p value OR C
GVD-IR 2.12 (1.23–3.64) 0.007 1.30 (
NFT-IR 2.47 (1.45–4.22) 0.001 1.61 (
Model 1 controlling for age and sex; model 2 additionally controlling for NFT and N
CI confidence interval, GVD granulovacuolar degeneration, IR immunoreactive, NFT
ing protein 43[38], and the phosphorylated ribosomal protein S6 (pS6)
revealed more neurons containing both NFT and GVD
than in our study [39], suggesting that GVD can be
missed in standard neuropathological protocols using
H & E. Thal et al. [15] suggest that tau is not a good
marker for GVD owing to its involvement with various
pathologies, and another candidate marker for GVD
(pS6) revealed more neurons containing both NFT and
GVD than in our study [39]; therefore it is possible that
GVD-IR is masked by immunoreactivity for NFT and
that our measures underestimate GVD when present in
NFT.
Our more detailed assessment of tau-IR NFT corre-
lated with that of the CERAD protocol moderately. The
CERAD score represents the highest score measured
over the entire hippocampal structure and our detailed
score is for CA1 only. However, since CA1 is often the
most severely affected hippocampal structure [4, 5], we
would expect good correlation. If the morphology of
tau-IR is not considered, there is potential for occasional
neurons severely affected by GVD and neurons with
both GVD and NFT to be misclassified as pure NFT, as
illustrated in Figs. 1 and 2. This may also contribute to
the moderate correlation found.
We found a significant association between both NFT
and GVD with dementia. However, when NFT and NP
were controlled for, the association between GVD and
dementia lost significance. This is in agreement withhips between hippocampal pathologies and severity of
Model 3
I p value OR CI p value
0.69–2.44) 0.422 1.31 (0.68–2.54) 0.417
0.84–3.10) 0.152 3.16 (1.48–6.71) 0.003
P; model 3 additionally controlling for TDP-43 and amyloid deposits
neurofibrillary tangles, NP neuritic plaques, OR odds ratio, TDP-43 Tar-DNA bind-
Fig. 1 GVD and NFT at the CA2–CA1 boundary. a CA2–CA1 boundary at 159× magnification; scale bar = 100 μm. b Marked area in A at 638×
magnification; scale bar = 20 μm: 1 NFT bearing neuron, 2, 3 neurons with both GVD granules and fibrils that under low power in A could be
mistaken for ‘pure’ NFT, 4 two neurons with diffuse tau staining lacking any clear morphology and showing a clear hard line around the nucleus,
5 a neuron with GVD also containing two larger discrete fibrous bundles, *examples of neurons with GVD. c The cell marked 3 at 1600× magnification
showing GVD and fibrils; scale bar = 20 μm. CA cornus ammonis, GVD granulovacuolar degeneration, NFT neurofibrillary tangles
Fig. 2 GVD and NFT progression in the hippocampal CA1 field. a Neurons in CA1 at 638× magnification showing various stages of GVD pathology:
1 a few granules in the neuronal cytoplasm staining weakly and one granule not at all for tau, 2, 3 more cytoplasmic granules develop and tau
staining increases in intensity, 4 the cell body is completely filled with strongly staining small GVD and could be mistaken for NFT, 5 the neuron
appears distended and the cell body is filled with large GVD with distended vacuoles. b, c, d CA1 neurons showing NFT progression at 638×
magnification: i neurons showing a possible early stage of NFT formation with lightly staining PHF fibres, ii neurons showing robust tau staining of
fibrous PHFs, iii ghost tangle. Scale bar = 20 μm. CA cornus ammonis, GVD granulovacuolar degeneration, NFT neurofibrillary tangles, PHF paired
helical filament
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Fig. 3 End stage ‘ghost’ GVD. a–f Examples of possible ‘ghost’ GVD. All panels at 638× magnification; scale bar = 20 μm. Arrows, deposits resembling
neurons with GVD but with no discernible living cell body or nucleus. GVD granulovacuolar degeneration
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with Ball [40], our results suggest that GVD severity in-
creases as NFT severity increases. A loss of significance
can mean that GVD is not an independent contributor
to dementia and so is ‘unimportant’ or that there is
some mechanism involving GVD, NFT and plaques that
undermines the assumption of independence for this
statistical test. With increasing evidence that NFT and
GVD share some features, including tau, and not others
(e.g., TDP-43 [41]), it is possible that loss of significance
reflects some shared process(es) rather than GVD not
being an important contributor to dementia. At a mech-
anistic level, various studies imply that GVD is a pre-
tangle and/or contributes to early NFT formation [42,
43]. This conflicts with other studies [12], including
ours, which present evidence that GVD can be inter-
preted as a separate process.
Our estimates of the associations between both sever-
ities of GVD and NFT and dementia status may be unre-
liable because only CA1 scores were included. For a
future detailed investigation of the relationships between
NFT, GVD and dementia, neocortical and subcortical
areas should be included [15].
In agreement with Bondareff et al. [12], in each available
case from the CC75C cohort affected by both NFT and
GVD we have observed neurons with classic fibrillar NFT
only, classic GVD only and, more rarely, neurons with both
NFT and GVD (Figs. 1 and 2). While these pathologies can
rarely occur together in the same neuron, we do not see
neurons in which GVD-like deposits can be interpreted as
developing into NFT following the generally accepted pro-
gression from pre-tangle to mature NFT to ghost tangle as
the CERAD protocol and other studies imply [42, 43]. Ra-
ther, NFT and GVD appear to have their own progression
in severity (Fig. 2) and their own ghost forms (Figs. 2 and
3). Given the associations between GVD and NFT and
dementia presented, our evidence supports previoussuggestions that the formation of NFT and GVD are separ-
ate processes that can co-occur in any individual [23].
In comparison, the accepted longitudinal progression
for NFT from pre-tangles to mature tangles to extracellu-
lar ghosts is also based on similar cross-sectional studies.
Our findings suggest that the widely accepted progression
of NFT may not be adequate to explain the variations in
tau-IR we present. We suggest that the pathways of both
granulovacuolar and neurofibrillary tau-IR pathology re-
quire careful evaluation to separate and understand the
relationships between these two processes and their in-
volvement in dementia. Additional processes may relate to
diffuse tau-IR seen in neurons marked in Fig. 2 and these
may be associated with AGD [36]. Definitions of what a
pre-tangle is need clarification.
Most GVD granules are labelled strongly with tau,
suggesting that tau is involved in the development of
GVD at an early stage. GVD shows an amorphous struc-
ture on electron micrographs [14, 19], shows no fluores-
cence with thioflavin S [13] and is not marked by mAbs
such as 7.51 [12], Alz-50 [25, 44], Tau-1 [17] and PHF-1
[16, 45] recognising epitopes specific to PHFs. The above
evidence suggests that PHFs, typical of NFT, are not
contained in GVD. Tau aggregation in GVD has been
interpreted as representing a second pathway of tau aggre-
gation [12]. Tau as a component of GVD will be missed
when using PHF reactive antibodies. Why some neurons
develop NFT, GVD or occasionally both is not known but
could arise owing to different stress responses in different
neuronal subtypes, different neurodegenerative processes
or different stress responses within the neurons. Investiga-
tions into the initiation and development of GVD may
offer alternative therapeutic targets.
Conclusions
Tau in a non-PHF-associated conformation is reliably as-
sociated with GVD. Current neuropathological protocols
Hunter et al. Alzheimer's Research & Therapy  (2015) 7:57 Page 9 of 10do not adequately capture the extent of tau-IR pathology
and require re-evaluation, in particular, to better assess
the contribution of GVD to dementia and differentiate
it from pathology of NFT. The relationships between
NFT, GVD and pre-tangles are unclear, which has con-
sequences for investigations into tau aggregation, espe-
cially at early stages of disease. We recommend that
protocols to assess GVD should be developed for rou-
tine use.
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